Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination

被引：6

作者：

Bauswein, Markus ^{[1
]}

Peterhoff, David ^{[1
,2
]}

Plentz, Annelie ^{[1
]}

Hiergeist, Andreas ^{[1
,2
]}

Wagner, Ralf ^{[1
,2
,3
]}

Gessner, Andre ^{[1
,2
]}

Salzberger, Bernd ^{[3
]}

Schmidt, Barbara ^{[1
,2
]}

Bauernfeind, Stilla ^{[3
]}

机构：

[1] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Regensburg, Germany

[2] Univ Regensburg, Inst Med Microbiol & Hyg, Regensburg, Germany

[3] Univ Hosp Regensburg, Dept Infect Prevent & Infect Dis, Regensburg, Germany

来源：

ISCIENCE | 2022年 / 25卷 / 02期

关键词：

NCOV-19;

D O I：

10.1016/j.isci.2021.103694

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower efficacy of this regimen. In the middle of 2021, the SARS-CoV-2 Delta variant of concern (VoC) has become predominant in many countries worldwide. Data addressing the neutralization capacity of a heterologous ChAdOx1 nCoV-19/mRNA-based vaccination approach against the Delta VoC in comparison to the widely used homologous mRNA-based vaccine regimen are limited. Here, we compare serological immune responses of a cohort of ChAdOx1 nCoV-19/ BNT162b2-vaccinated participants with those of BNT162b2/BNT162b2 vaccinated ones and show that neutralization capacity against the Delta VoC is significantly increased in sera of ChAdOx1 nCoV-19/BNT162b2-vaccinated participants. This overall effect can be attributed to ChAdOx1 nCoV-19/BNT162b2-vaccinated women, especially those with more severe adverse effects leading to sick leave following second immunization.

引用

页数：13

共 50 条

[41] First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence [J].

Murillo-Zamora, E. ;

Trujillo, X. ;

Huerta, M. ;

Rios-Silva, M. ;

Lugo-Radillo, A. ;

Baltazar-Rodriguez, L. M. ;

Mendoza-Cano, O. .

PUBLIC HEALTH, 2022, 207 :105-107

[42] A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222 [J].

Nantanee, Rapisa ;

Jantarabenjakul, Watsamon ;

Jaru-Ampornpan, Peera ;

Sodsai, Pimpayao ;

Himananto, Orawan ;

Athipunjapong, Jitthiwa ;

Sophonphan, Jiratchaya ;

Nanthapisal, Sira ;

Hirankarn, Nattiya ;

Puthanakit, Thanyawee .

VACCINES, 2022, 10 (06)

[43] Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization [J].

Wong, Carlos King Ho ;

Xiong, Xi ;

Lau, Kristy Tsz Kwan ;

Chui, Celine Sze Ling ;

Lai, Francisco Tsz Tsun ;

Li, Xue ;

Chan, Esther Wai Yin ;

Wan, Eric Yuk Fai ;

Au, Ivan Chi Ho ;

Cowling, Benjamin John ;

Lee, Cheuk Kwong ;

Wong, Ian Chi Kei .

BMC MEDICINE, 2022, 20 (01)

[44] Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly [J].

Ferreira, Isabella A. T. M. ;

Lee, Colin Y. C. ;

Foster, William S. ;

Abdullahi, Adam ;

Dratva, Lisa M. ;

Tuong, Zewen Kelvin ;

Stewart, Benjamin J. ;

Ferdinand, John R. ;

Guillaume, Stephane M. ;

Potts, Martin O. P. ;

Perera, Marianne ;

Krishna, Benjamin A. ;

Penalver, Ana ;

Cabantous, Mia ;

Kemp, Steven A. ;

Ceron-Gutierrez, Lourdes ;

Lyons, Paul ;

Smith, Kenneth G. C. ;

Bradley, John ;

Collier, Dami A. ;

Mccoy, Laura E. ;

van der Klaauw, Agatha ;

Thaventhiran, James E. D. ;

Farooqi, I. Sadaf ;

Teichmann, Sarah A. ;

Macary, Paul A. ;

Doffinger, Rainer ;

Wills, Mark R. ;

Linterman, Michelle A. ;

Clatworthy, Menna R. ;

Gupta, Ravindra K. .

CELL REPORTS, 2023, 42 (08)

[45] Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh [J].

Al-Emran, Hassan M. ;

Hasan, Md. Shazid ;

Setu, Md. AliAhasan ;

Rahman, M. Shaminur ;

Ul Alam, A. S. M. Rubayet ;

Sarkar, Shovon Lal ;

Islam, Md. Tanvir ;

Islam, Mir Raihanul ;

Rahman, Mohammad Mahfuzu ;

Islam, Ovinu Kibria ;

Jahid, Iqbal Kabir ;

Hossain, M. Anwar .

JOURNAL OF INFECTION AND PUBLIC HEALTH, 2022, 15 (02) :156-163

[46] Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2 [J].

Lee, Sang Won ;

Lee, Hyun ;

Lee, Sun-Kyung ;

Moon, Ji-Yong ;

Moon, SeolHwa ;

Chung, Sung Jun ;

Yeo, Yoomi ;

Park, Tai Sun ;

Park, Dong Won ;

Kim, Tae-Hyung ;

Sohn, Jang Won ;

Yoon, Ho Joo ;

Kim, Sang-Heon .

FRONTIERS IN MEDICINE, 2021, 8

[47] Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age [J].

Tanner, Richard ;

Starr, Neasa ;

Chan, Grace ;

Dempsey, Eimear ;

Heffernan, Emma ;

Newman, Ellen ;

O'Neill, James ;

Hannan, Margaret M. ;

Lynch, Breda ;

Joyce, Emer .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04) :492-500

[48] Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial [J].

Asano, Michiko ;

Okada, Hiroshi ;

Itoh, Yohji ;

Hirata, Hajime ;

Ishikawa, Kensuke ;

Yoshida, Erika ;

Matsui, Akiko ;

Kelly, Elizabeth J. ;

Shoemaker, Kathryn ;

Olsson, Urban ;

Vekemans, Johan .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 114 :165-174

[49] Reactogenicity and persistence of IgG antibodies against SARS-CoV-2 among recipients of ChAdOx1 nCoV-19 vaccine: A single center experience from Sri Lanka [J].

Govindapala, Dumitha ;

Dhanaratna, Dhanuka ;

Senarath, Uththara ;

Lamabadusuriya, Dilusha ;

Senaratne, Thamarasi ;

Wijenayake, Wasantha ;

Wijewardena, Dasun ;

Nakkawita, Dilini ;

Kawyangana, Pawanie ;

Kulasekara, Upeksha ;

Dharshan De Silva, Aruna ;

Fernando, Nayana .

INTERNATIONAL JOURNAL OF HEALTH SCIENCES-IJHS, 2023, 17 (01) :36-43

[50] Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005) [J].

Koen, Anthonet L. ;

Izu, Alane ;

Baillie, Vicky ;

Kwatra, Gaurav ;

Cutland, Clare L. ;

Fairlie, Lee ;

Padayachee, Sherman D. ;

Dheda, Keertan ;

Barnabas, Shaun L. ;

Bhorat, Qasim Ebrahim ;

Briner, Carmen ;

Ahmed, Khatija ;

Bhikha, Sutika ;

Bhiman, Jinal N. ;

du Plessis, Jeanine ;

Esmail, Aliasgar ;

Horne, Elizea ;

Hwa, Shi-Hsia ;

Oommen-Jose, Aylin ;

Lambe, Teresa ;

Laubscher, Matt ;

Malahleha, Mookho ;

Benade, Gabriella ;

McKenzie, Shakeel ;

Oelofse, Suzette ;

Patel, Faeezah ;

Pillay, Sureshnee ;

Rhead, Sarah ;

Rodel, Hylton ;

Taoushanis, Carol ;

Tegally, Houriiyah ;

Thombrayil, Asha ;

Villafana, Tonya L. ;

Gilbert, Sarah ;

Pollard, Andrew J. ;

Madhi, Shabir A. .

VACCINE, 2023, 41 (23) :3486-3492

← 1 2 3 4 5 →